A snapshot of key appointments recently announced
GlaxoSmithKline
Andrew Witty, currently president, Pharmaceuticals Europe for GSK, has been appointed Chief Executive Officer designate of GlaxoSmithKline. Witty will succeed Dr. Jean-Pierre Garnier following his retirement as CEO at the end of May 2008.
Celsis International
Philip Vorwald has been appointed Vice President and General Manager of Celsis International's In Vitro Technologies (Celsis IVT) division, with responsibility for setting and overseeing the long-term growth strategy of the company's ADME-Tox products. Vorwald will report to Jay LeCoque, Celsis International's CEO.
RSA
Dr Patricia Lobo has been appointed Managing Partner of the RSA Consulting division of RSA with responsibility for developing and managing the division, reporting to Mr Keith Hobson, Chief Operating Officer. RSA is the leading provider of resourcing services to the Lifescience and Healthcare sectors. Patricia brings into RSA, over thirty years of industrial experience, 14 years of which were with Technomark Consulting Services. Further information
Quintiles
Jay D. Norman has been appointed president of Quintiles Consulting business. The unit's offerings include strategic product development, regulatory compliance, and pricing & reimbursement.
Pfizer
Dr. Martin Mackay has been named president of Pfizer Global Research and Development (PGRD), an independent biotherapeutics and bioinnovation center under the direction of scientist Dr Corey Goodman. In a separate move Dr. Briggs Morrison has been named head of clinical development for the PGRD pipeline.
Keywords : Company News, Management changes, Appointments, GSK, Celsis, RSA Consulting, Quintiles, Pfizer
